Molecular Partners (MOLN)

• Market cap: $158M
• 1 day: 4.73%
• 5 days: 2.55%
• 1 month: 10.2%
• 3 months: 20.38%
• 6 months: 15.97%
• Year to date: -9.03%
• 1 year: -11.22%
• 5 years: -77.46%
• 10 years: -77.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Employees: 159